Biosimilars

Biosimilars are a rapidly growing treatment option for physicians treating advanced diseases, with more than 20 unique biosimilars expected to enter the U.S. healthcare market over the next decade. Learn more about these safe and effective treatment options.

  • VIDEO

    Uncovering the Path to Successful Biosimilar Adoption for Your Specialty Practice

    If your specialty practice is preparing to adopt biosimilars, McKesson can help. We clear the path by creating a roadmap for success. Our advisors and resources can help you navigate every step of the biosimilar journey, from patient education to developing training programs. McKesson also supports specialty practices like yours with communicating the facts clearly, implementing efficient workflows and driving operational excellence so you can focus on what matters most - caring for your patients.

 

Read below for biosimilar resources at every stage: biosimilar beginners, considerations when using biosimilars, and best practices post-adoption.

 

New to biosimilars?

  • Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from existing, FDA-approved reference biologics.
  • While biosimilars are similar to their reference biological product, they are not generic equivalents.
  • Biosimilars go through a rigorous FDA review process including analytical, animal and clinical studies.

Biosimilars go through an extensive FDA approval process and offer safe, effective therapeutic options for serious diseases

As more biosimilars become available in the U.S., providers, payers and patients all stand to benefit from further incorporating these safe and effective therapies throughout our healthcare ecosystem.

Rising healthcare costs, increasing drug production demands and reimbursement pressures are all putting a serious strain on our nation’s healthcare delivery system. By adopting biosimilars routinely into patient treatment decisions, we can improve overall access to critical, life-saving drugs all while reducing the costs of these expensive therapies through increased competition.

Learn more about the McKesson services available to support biosimilar and other practice needs by visiting our Solutions for Specialty Practices page.

Considering adopting biosimilars in your treatment regimens?

Biosimilars Currently Available through McKesson Include:

Biosimilar Drug

Biologic Reference Drug

HCPCS Code 

Patient Support Services

Full Prescribing Information

Mvasi
(bevacizumab-awwb)

Avastin

Q5107

Amgen Assist 360

FDA Drug Info (PDF, 627 KB)

Zirabev
(bevacizumab-bvzr)

Avastin

Q5118

Pfizer Oncology Together

FDA Drug Info (PDF, 1 MB)

Retacrit
(epoetin alfa-epbx)

Epogen/Procrit

Q5105 (ESRD use)
Q5106 (non-ESRD use)

Pfizer enCompassProgram

FDA Drug Info (PDF, 614 KB)

Herzuma
(trastuzumab-pkrb)

Herceptin

Q5113

Teva Core Program

FDA Drug Info (PDF, 551 KB)

Kanjinti
(trastuzumab-anns)

Herceptin

Q5117

Amgen Assist 360

FDA Drug Info (PDF, 834 KB)

Ogiviri
(trastuzumab-dkst)

Herceptin

Q5114

Mylan Advocate Portal

FDA Drug Info

Ontruzant
(trastuzumab-dttb)

Herceptin

Q5112

Merck Access Program

FDA Drug Info

Trazimera
(trastuzumab-qyyp)

Herceptin

Q5116

Pfizer Oncology Together

FDA Drug Info (PDF, 706 KB)

Fulphila
(pegfilgrastim-jmdb)

Neulasta

Q5108

Mylan Advocate Portal

FDA Drug Info (PDF, 921 KB)

Nyvepria
(pegfilgrastim-apgf)

Neulasta

Q5122

Pfizer Oncology Together

FDA Drug Info (PDF, 1 MB)

Udenyca
(pegfilgrastim-cbqv)

Neulasta

Q5111

Coherus COMPLETE | Support

FDA Drug Info (PDF, 1 MB)

Ziextenzo
(pegfilgrastim-bmez)

Neulasta

Q5120

Sandoz One Source

FDA Drug Info

Nivestym
(filgrastim-aafi)

Neupogen

Q5110

Pfizer enCompass

FDA Drug Info (PDF, 921 KB)

Zarxio
(filgrastim-sndz)

Neupogen

Q5101

Sandoz OneSource

FDA Drug Info (PDF, 3 MB)

Avsola
(infliximab-axxq)

Remicade

Q5121

Amgen Assist

FDA Drug Info  

Inflectra
(infliximab-dyyb)

Remicade

Q5103

Pfizer enCompass

FDA Drug Info (PDF, 1 MB)

Renflexis
(infliximab-abda)

Remicade

Q5104

Merck Access Program

FDA Drug Info (PDF, 537 KB)

Riabni
(rituximab-arrx)

Rituxan

Q5123

Amgen Assist 360

FDA Drug Info (PDF, 468 KB)

Ruxience
(rituximab-pvvr)

Rituxan

Q5119

Pfizer Oncology Together

FDA Drug Info (PDF, 811 KB)

Truxima
(rituximab-abbs)

Rituxan

Q5115

Teva Core Program

FDA Drug Info (PDF, 402 KB)

Contact Us

Specialty DistributionSpecialty drugs for physician practices.

Specialty Customer LoginPhysician practice login.

Pharmacy DistributionFor pharmacies, health systems & hospitals.

  • Four Reasons to Consider Adopting Biosimilars for Your Treatment Regimens

    Expand Treatment Options for Complex Diseases

    nb-cash

    Substantial Cost Savings on Expensive Therapies

    nb-pharmaceutical-mnf-building

    FDA-Approved, Safe and Effective Treatments

    z-thought-leadership-n

    Support from FDA and Other Leading Medical Advisory Organizations

  • BIOSIMILAR 101 RESOURCES

    A Guide to Navigating Biosimilars

    From 2017 to 2020, McKesson helped specialty providers save more than $386 million dollars through biosimilar adoption. As the biosimilar landscape continues to evolve, we can expect to see more biosimilar treatment options for more conditions. McKesson is here to help you navigate the landscape, identify economic opportunities for your practice and provide resources to physicians who are evaluating biosimilars for their patients.

  • ADDITIONAL READING

    Biosimilar Perspectives from McKesson Experts

    Navigating Biosimilar Reimbursement: Key Challenges and Steps to Success
    McKesson’s experts address the most important clinical, operational, and economical obstacles to overcome on the path to reimbursement.

    Three Biosimilar Barriers in Community Clinic
    An in depth look at the primary concerns of physicians when implementing biosimilars in their oncology and rheumatology practices.

    From Clinical Use to Reimbursement
    Dr. Robert Rifkin, medical director of biosimilars for McKesson, gives an update on biosimilar education and reimbursement.

    Perfect Storm for Biosimilar Marketing
    Dr. Robert Rifkin discusses the "perfect storm" for biosimilar marketing in a recent OncLive article.

    Biosimilars: A Recent Review of Clinical Outcomes
    A review of 14,000 individuals transitioned from a reference biologic medication to a biosimilar examines patient safety and treatment efficacy.

    Overcoming Physician Barriers to Biosimilar Adoption in Clinics (PDF, 228 KB)
    Omar Hafez shares how biopharmaceutical companies can learn how to overcome the clinical, operational, and economic barriers to biosimilar adoption.

  • VIEWPOINT

    Biosimilar Endorsements From Major Medical Advisory Organizations

    Read about the benefits of biosimilar growth from major Oncology and Rheumatology advisory bodies.

    Rheumatology | Oncology (PDF, 648 KB)

  • EDUCATION

    CMS Medicare Guidance on Biosimilar Reimbursement
    Stay up to date on new Medicare HCPCS codes and reimbursement guidance on biosimilars.

    FDA Biosimilar Resources for Your Practice
    Visit the FDA biosimilar website for provider and patient-facing biosimilar resources. Topics include the latest FDA approvals, biosimilar 101 education, regulatory review and approval, interchangeability guidance and more.